BACKGROUND: Most of the millions of oral contraceptive (OC) users are under 30 years of age and in the critical period for bone mass accrual. STUDY DESIGN: This cross-sectional study of 606 women aged 14-30 years examined both OC duration and estrogen dose and their association with bone mineral density (BMD) at the hip, spine, and whole body (dual-energy X-ray absorptiometry). RESULTS: Of 389 OC users and 217 nonusers enrolled, 50% were adolescents (14-18 years). Of OC users, 38% used "low-dose" OCs [<30 mcg ethinyl estradiol (EE)]. In adolescents, mean BMD differed by neither OC duration nor EE dose. However, 19- to 30-year-old women's mean BMD was lower with longer OC use for spine and whole body (p=.004 and p=.02, respectively) and lowest for >12 months of low-dose OCs for the hip, spine and whole body (p=.02, .003 and .002, respectively). CONCLUSIONS: Prolonged use of today's OCs, particularly <30 mcg EE, may adversely impact young adult women's bone density while using these agents.
BACKGROUND: Most of the millions of oral contraceptive (OC) users are under 30 years of age and in the critical period for bone mass accrual. STUDY DESIGN: This cross-sectional study of 606 women aged 14-30 years examined both OC duration and estrogen dose and their association with bone mineral density (BMD) at the hip, spine, and whole body (dual-energy X-ray absorptiometry). RESULTS: Of 389 OC users and 217 nonusers enrolled, 50% were adolescents (14-18 years). Of OC users, 38% used "low-dose" OCs [<30 mcg ethinyl estradiol (EE)]. In adolescents, mean BMD differed by neither OC duration nor EE dose. However, 19- to 30-year-old women's mean BMD was lower with longer OC use for spine and whole body (p=.004 and p=.02, respectively) and lowest for >12 months of low-dose OCs for the hip, spine and whole body (p=.02, .003 and .002, respectively). CONCLUSIONS: Prolonged use of today's OCs, particularly <30 mcg EE, may adversely impact young adult women's bone density while using these agents.
Authors: Susan D Reed; Delia Scholes; Andrea Z LaCroix; Laura E Ichikawa; William E Barlow; Susan M Ott Journal: Contraception Date: 2003-09 Impact factor: 3.375
Authors: J C Prior; S A Kirkland; L Joseph; N Kreiger; T M Murray; D A Hanley; J D Adachi; Y M Vigna; C Berger; L Blondeau; S A Jackson; A Tenenhouse Journal: CMAJ Date: 2001-10-16 Impact factor: 8.262
Authors: Manfred Hartard; Christine Kleinmond; Michael Wiseman; Ernst R Weissenbacher; Dieter Felsenberg; Reinhold G Erben Journal: Bone Date: 2006-09-11 Impact factor: 4.398
Authors: Delia Scholes; Rebecca A Hubbard; Laura E Ichikawa; Andrea Z LaCroix; Leslie Spangler; Jeannette M Beasley; Susan Reed; Susan M Ott Journal: J Clin Endocrinol Metab Date: 2011-07-13 Impact factor: 5.958
Authors: Joshua N Farr; Sundeep Khosla; Sara J Achenbach; Elizabeth J Atkinson; Salman Kirmani; Louise K McCready; L Joseph Melton; Shreyasee Amin Journal: J Bone Miner Res Date: 2014-10 Impact factor: 6.741
Authors: Kathryn E Ackerman; Vibha Singhal; Meghan Slattery; Kamryn T Eddy; Mary L Bouxsein; Hang Lee; Anne Klibanski; Madhusmita Misra Journal: J Bone Miner Res Date: 2019-11-07 Impact factor: 6.741
Authors: Amber S Kujath; Lauretta Quinn; Mary E Elliott; Tamara J LeCaire; Neil Binkley; Andrea R Molino; Kirstie K Danielson Journal: Diabetes Metab Res Rev Date: 2015-01-21 Impact factor: 4.876
Authors: Hawley C Almstedt; Makenzie M Cook; Lily F Bramble; Deepa V Dabir; Joseph W LaBrie Journal: J Bone Miner Metab Date: 2020-01-25 Impact factor: 2.626